Diseases /
Ovarian Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A malignant neoplasm originating from the surface ovarian epithelium. It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women. It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups. Adenocarcinomas constitute the vast majority of ovarian carcinomas. The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type. The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver. Lung and pleura are the most common sites of extra-abdominal spread. The primary form of therapy is surgical. The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms. [1]
Ovarian carcinomas most frequently harbor alterations in TP53, KRAS, CCNE1, PIK3CA, and NF1 [2].
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, TP53 Exon 5 Mutation, and TP53 Exon 8 Mutation are the most common alterations in ovarian carcinoma [2].
Clinical Trials
There are 291 clinical trials for ovarian carcinoma, of which 210 are open and 81 are completed or closed. Of the trials that contain ovarian carcinoma as an inclusion criterion, 5 are early phase 1 (5 open), 136 are phase 1 (86 open), 66 are phase 1/phase 2 (51 open), 68 are phase 2 (53 open), 1 is phase 2/phase 3 (1 open), 13 are phase 3 (12 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open).
BRCA1, BRCA2, and ATM are the most frequent gene inclusion criteria for ovarian carcinoma clinical trials [3].
Pembrolizumab, paclitaxel, and olaparib are the most common interventions in ovarian carcinoma clinical trials.
Significant Genes in Ovarian Carcinoma
ABCB1 +
ABCB1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ABCB1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].
AKT1 +
AKT1 is altered in 1.19% of ovarian carcinoma patients [2].
AKT1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
AKT2 +
AKT2 is altered in 3.39% of ovarian carcinoma patients [2].
AKT2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
AKT3 +
AKT3 is altered in 1.15% of ovarian carcinoma patients [2].
AKT3 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ARAF +
ARAF is altered in 2.48% of ovarian carcinoma patients [2].
ARAF is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARAF status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
ARID1A +
ARID1A is altered in 6.45% of ovarian carcinoma patients [2].
ARID1A is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ARID1A status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
ATM +
ATM is altered in 4.06% of ovarian carcinoma patients [2].
ATM is an inclusion eligibility criterion in 20 clinical trials for ovarian carcinoma, of which 15 are open and 5 are closed. Of the trials that contain ATM status and ovarian carcinoma as inclusion criteria, 6 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), 8 are phase 2 (7 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
ATR +
ATR is altered in 2.32% of ovarian carcinoma patients [2].
ATR is an inclusion eligibility criterion in 15 clinical trials for ovarian carcinoma, of which 10 are open and 5 are closed. Of the trials that contain ATR status and ovarian carcinoma as inclusion criteria, 6 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].
ATRX +
ATRX is altered in 4.1% of ovarian carcinoma patients [2].
ATRX is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATRX status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
BACH1 +
BACH1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BACH1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
BARD1 +
BARD1 is altered in 1.21% of ovarian carcinoma patients [2].
BARD1 is an inclusion eligibility criterion in 17 clinical trials for ovarian carcinoma, of which 13 are open and 4 are closed. Of the trials that contain BARD1 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
BCL2 +
BCL2 is altered in 0.4% of ovarian carcinoma patients [2].
BCL2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
BCL6 +
BCL6 is altered in 1.97% of ovarian carcinoma patients [2].
BCL6 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
BRAF +
BRAF is altered in 2.24% of ovarian carcinoma patients [2].
BRAF is an inclusion eligibility criterion in 6 clinical trials for ovarian carcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRAF status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].
BRCA1 +
BRCA1 is altered in 7.82% of ovarian carcinoma patients [2].
BRCA1 is an inclusion eligibility criterion in 40 clinical trials for ovarian carcinoma, of which 32 are open and 8 are closed. Of the trials that contain BRCA1 status and ovarian carcinoma as inclusion criteria, 3 are early phase 1 (3 open), 10 are phase 1 (7 open), 8 are phase 1/phase 2 (7 open), 14 are phase 2 (11 open), 4 are phase 3 (3 open), and 1 is phase 4 (1 open) [3].
BRCA2 +
BRCA2 is altered in 6.25% of ovarian carcinoma patients [2].
BRCA2 is an inclusion eligibility criterion in 40 clinical trials for ovarian carcinoma, of which 32 are open and 8 are closed. Of the trials that contain BRCA2 status and ovarian carcinoma as inclusion criteria, 3 are early phase 1 (3 open), 10 are phase 1 (7 open), 8 are phase 1/phase 2 (7 open), 14 are phase 2 (11 open), 4 are phase 3 (3 open), and 1 is phase 4 (1 open) [3].
BRIP1 +
BRIP1 is altered in 1.88% of ovarian carcinoma patients [2].
BRIP1 is an inclusion eligibility criterion in 17 clinical trials for ovarian carcinoma, of which 13 are open and 4 are closed. Of the trials that contain BRIP1 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
C11ORF30 +
C11orf30 is altered in 0.77% of ovarian carcinoma patients [2].
C11orf30 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain C11orf30 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
CCNE1 +
CCNE1 is altered in 8.86% of ovarian carcinoma patients [2].
CCNE1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CCNE2 +
CCNE2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CDK12 +
CDK12 is altered in 4.21% of ovarian carcinoma patients [2].
CDK12 is an inclusion eligibility criterion in 18 clinical trials for ovarian carcinoma, of which 13 are open and 5 are closed. Of the trials that contain CDK12 status and ovarian carcinoma as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
CDKN2A +
CDKN2A is altered in 3.32% of ovarian carcinoma patients [2].
CDKN2A is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
CHEK1 +
CHEK1 is altered in 0.44% of ovarian carcinoma patients [2].
CHEK1 is an inclusion eligibility criterion in 16 clinical trials for ovarian carcinoma, of which 12 are open and 4 are closed. Of the trials that contain CHEK1 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 6 are phase 2 (5 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
CHEK2 +
CHEK2 is altered in 1.44% of ovarian carcinoma patients [2].
CHEK2 is an inclusion eligibility criterion in 17 clinical trials for ovarian carcinoma, of which 13 are open and 4 are closed. Of the trials that contain CHEK2 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
CRKL +
CRKL is altered in 1.46% of ovarian carcinoma patients [2].
CRKL is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
EGFR +
EGFR is altered in 1.36% of ovarian carcinoma patients [2].
EGFR is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
ERBB2 +
ERBB2 is altered in 3.28% of ovarian carcinoma patients [2].
ERBB2 is an inclusion eligibility criterion in 7 clinical trials for ovarian carcinoma, of which 5 are open and 2 are closed. Of the trials that contain ERBB2 status and ovarian carcinoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
ERBB3 +
ERBB3 is altered in 1.92% of ovarian carcinoma patients [2].
ERBB3 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
ERCC2 +
ERCC2 is altered in 1.96% of ovarian carcinoma patients [2].
ERCC2 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC2 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
ERCC3 +
ERCC3 is altered in 0.82% of ovarian carcinoma patients [2].
ERCC3 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC3 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
ERCC4 +
ERCC4 is altered in 0.85% of ovarian carcinoma patients [2].
ERCC4 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC4 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
ERCC5 +
ERCC5 is altered in 1.45% of ovarian carcinoma patients [2].
ERCC5 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC5 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
ERCC6 +
ERCC6 is altered in 0.52% of ovarian carcinoma patients [2].
ERCC6 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC6 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
FANCA +
FANCA is altered in 2.22% of ovarian carcinoma patients [2].
FANCA is an inclusion eligibility criterion in 16 clinical trials for ovarian carcinoma, of which 12 are open and 4 are closed. Of the trials that contain FANCA status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (0 open) [3].
FANCB +
FANCB is altered in 1.81% of ovarian carcinoma patients [2].
FANCB is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCB status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].
FANCC +
FANCC is altered in 1.14% of ovarian carcinoma patients [2].
FANCC is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCC status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].
FANCD2 +
FANCD2 is altered in 1.85% of ovarian carcinoma patients [2].
FANCD2 is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCD2 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].
FANCE +
FANCE is altered in 1.7% of ovarian carcinoma patients [2].
FANCE is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCE status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].
FANCF +
FANCF is altered in 0.96% of ovarian carcinoma patients [2].
FANCF is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCF status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].
FANCG +
FANCG is altered in 0.91% of ovarian carcinoma patients [2].
FANCG is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCG status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].
FANCI +
FANCI is altered in 2.39% of ovarian carcinoma patients [2].
FANCI is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCI status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].
FANCL +
FANCL is altered in 1.13% of ovarian carcinoma patients [2].
FANCL is an inclusion eligibility criterion in 16 clinical trials for ovarian carcinoma, of which 12 are open and 4 are closed. Of the trials that contain FANCL status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 6 are phase 2 (5 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
FANCM +
FANCM is altered in 2.53% of ovarian carcinoma patients [2].
FANCM is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCM status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].
FGFR2 +
FGFR2 is altered in 1.53% of ovarian carcinoma patients [2].
FGFR2 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
FLT3 +
FLT3 is altered in 1.56% of ovarian carcinoma patients [2].
FLT3 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
HDAC1 +
HDAC1 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain HDAC1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain HDAC2 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
HRAS +
HRAS is altered in 0.46% of ovarian carcinoma patients [2].
HRAS is an inclusion eligibility criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HRAS status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].
IDH1 +
IDH1 is altered in 0.36% of ovarian carcinoma patients [2].
IDH1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain IDH1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
KDR +
KDR is altered in 1.67% of ovarian carcinoma patients [2].
KDR is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
KIT +
KIT is altered in 1.69% of ovarian carcinoma patients [2].
KIT is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
KRAS +
KRAS is altered in 10.16% of ovarian carcinoma patients [2].
KRAS is an inclusion eligibility criterion in 8 clinical trials for ovarian carcinoma, of which 5 are open and 3 are closed. Of the trials that contain KRAS status and ovarian carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [3].
MAP2K1 +
MAP2K1 is altered in 0.51% of ovarian carcinoma patients [2].
MAP2K1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MAP2K2 +
MAP2K2 is altered in 1.32% of ovarian carcinoma patients [2].
MAP2K2 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MAP2K4 +
MAP2K4 is altered in 1.82% of ovarian carcinoma patients [2].
MAP2K4 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K4 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MAP3K1 +
MAP3K1 is altered in 2.38% of ovarian carcinoma patients [2].
MAP3K1 is an inclusion eligibility criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MAP3K1 status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MAPK1 +
MAPK1 is altered in 1.1% of ovarian carcinoma patients [2].
MAPK1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAPK1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MCL1 +
MCL1 is altered in 2.75% of ovarian carcinoma patients [2].
MCL1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCL1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 10 clinical trials for ovarian carcinoma, of which 6 are open and 4 are closed. Of the trials that contain MCPH1 status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 1 is phase 3 (0 open) [3].
MDM2 +
MDM2 is altered in 1.61% of ovarian carcinoma patients [2].
MDM2 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MDM2 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
MDM4 +
MDM4 is altered in 0.52% of ovarian carcinoma patients [2].
MDM4 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MDM4 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
MET +
MET is altered in 1.59% of ovarian carcinoma patients [2].
MET is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
MLF1 +
MLF1 is altered in 0.61% of ovarian carcinoma patients [2].
MLF1 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MLF1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
MLH1 +
MLH1 is altered in 0.88% of ovarian carcinoma patients [2].
MLH1 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MLH1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
MLH3 +
MLH3 is altered in 2.46% of ovarian carcinoma patients [2].
MLH3 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MLH3 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
MRE11A +
MRE11A is altered in 1.03% of ovarian carcinoma patients [2].
MRE11A is an inclusion eligibility criterion in 15 clinical trials for ovarian carcinoma, of which 11 are open and 4 are closed. Of the trials that contain MRE11A status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (0 open) [3].
MSH2 +
MSH2 is altered in 2.13% of ovarian carcinoma patients [2].
MSH2 is an inclusion eligibility criterion in 6 clinical trials for ovarian carcinoma, of which 4 are open and 2 are closed. Of the trials that contain MSH2 status and ovarian carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
MSH3 +
MSH3 is altered in 0.52% of ovarian carcinoma patients [2].
MSH3 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MSH3 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
MSH6 +
MSH6 is altered in 2.05% of ovarian carcinoma patients [2].
MSH6 is an inclusion eligibility criterion in 6 clinical trials for ovarian carcinoma, of which 4 are open and 2 are closed. Of the trials that contain MSH6 status and ovarian carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
MTOR +
MTOR is altered in 2.69% of ovarian carcinoma patients [2].
MTOR is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
MUTYH +
MUTYH is altered in 0.87% of ovarian carcinoma patients [2].
MUTYH is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MUTYH status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
MYC +
MYC is altered in 7.33% of ovarian carcinoma patients [2].
MYC is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 2 are open and 2 are closed. Of the trials that contain MYC status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (2 open) [3].
NBN +
NBN is altered in 1.63% of ovarian carcinoma patients [2].
NBN is an inclusion eligibility criterion in 16 clinical trials for ovarian carcinoma, of which 12 are open and 4 are closed. Of the trials that contain NBN status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (0 open) [3].
NF1 +
NF1 is altered in 8.01% of ovarian carcinoma patients [2].
NF1 is an inclusion eligibility criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NF1 status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
NPM1 +
NPM1 is altered in 0.33% of ovarian carcinoma patients [2].
NPM1 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain NPM1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
NRAS +
NRAS is altered in 2.13% of ovarian carcinoma patients [2].
NRAS is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 2 are open and 2 are closed. Of the trials that contain NRAS status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].
NTRK1 +
NTRK1 is altered in 2.4% of ovarian carcinoma patients [2].
NTRK1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
PALB2 +
PALB2 is altered in 1.45% of ovarian carcinoma patients [2].
PALB2 is an inclusion eligibility criterion in 19 clinical trials for ovarian carcinoma, of which 15 are open and 4 are closed. Of the trials that contain PALB2 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), 8 are phase 2 (7 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
PARP1 +
PARP1 is altered in 1.05% of ovarian carcinoma patients [2].
PARP1 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PARP1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
PARP2 +
PARP2 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PARP2 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
PCNA +
PCNA is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PDGFRA +
PDGFRA is altered in 1.51% of ovarian carcinoma patients [2].
PDGFRA is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
PIK3C2B +
PIK3C2B is altered in 3.17% of ovarian carcinoma patients [2].
PIK3C2B is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
PIK3CA +
PIK3CA is altered in 6.98% of ovarian carcinoma patients [2].
PIK3CA is an inclusion eligibility criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PIK3CA status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
PIK3CG +
PIK3CG is altered in 1.01% of ovarian carcinoma patients [2].
PIK3CG is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PIK3R1 +
PIK3R1 is altered in 2.63% of ovarian carcinoma patients [2].
PIK3R1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3R1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].
PIK3R2 +
PIK3R2 is altered in 2.63% of ovarian carcinoma patients [2].
PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PMS1 +
PMS1 is altered in 1.39% of ovarian carcinoma patients [2].
PMS1 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PMS1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
PMS2 +
PMS2 is altered in 0.82% of ovarian carcinoma patients [2].
PMS2 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PMS2 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
POLE +
POLE is altered in 1.66% of ovarian carcinoma patients [2].
POLE is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain POLE status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
PPP2R1A +
PPP2R1A is altered in 2.6% of ovarian carcinoma patients [2].
PPP2R1A is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PPP2R1A status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 6 clinical trials for ovarian carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PPP2R2A status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 4 (1 open) [3].
PTEN +
PTEN is altered in 4.06% of ovarian carcinoma patients [2].
PTEN is an inclusion eligibility criterion in 12 clinical trials for ovarian carcinoma, of which 7 are open and 5 are closed. Of the trials that contain PTEN status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), 5 are phase 2 (4 open), and 1 is phase 3 (0 open) [3].
RAD50 +
RAD50 is altered in 1.05% of ovarian carcinoma patients [2].
RAD50 is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain RAD50 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].
RAD51 +
RAD51 is altered in 0.48% of ovarian carcinoma patients [2].
RAD51 is an inclusion eligibility criterion in 15 clinical trials for ovarian carcinoma, of which 11 are open and 4 are closed. Of the trials that contain RAD51 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (0 open) [3].
RAD51B +
RAD51B is altered in 0.19% of ovarian carcinoma patients [2].
RAD51B is an inclusion eligibility criterion in 17 clinical trials for ovarian carcinoma, of which 13 are open and 4 are closed. Of the trials that contain RAD51B status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
RAD51C +
RAD51C is altered in 0.85% of ovarian carcinoma patients [2].
RAD51C is an inclusion eligibility criterion in 19 clinical trials for ovarian carcinoma, of which 15 are open and 4 are closed. Of the trials that contain RAD51C status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), 8 are phase 2 (7 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
RAD51D +
RAD51D is altered in 1.09% of ovarian carcinoma patients [2].
RAD51D is an inclusion eligibility criterion in 18 clinical trials for ovarian carcinoma, of which 14 are open and 4 are closed. Of the trials that contain RAD51D status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
RAD54L +
RAD54L is altered in 0.46% of ovarian carcinoma patients [2].
RAD54L is an inclusion eligibility criterion in 16 clinical trials for ovarian carcinoma, of which 12 are open and 4 are closed. Of the trials that contain RAD54L status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 6 are phase 2 (5 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
RAF1 +
RAF1 is altered in 0.74% of ovarian carcinoma patients [2].
RAF1 is an inclusion eligibility criterion in 3 clinical trials for ovarian carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAF1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
RET +
RET is altered in 1.63% of ovarian carcinoma patients [2].
RET is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
RFC1 +
RFC1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC2 +
RFC2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC3 +
RFC3 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC4 +
RFC4 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC5 +
RFC5 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RICTOR +
RICTOR is altered in 2.13% of ovarian carcinoma patients [2].
RICTOR is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
RPA2 +
RPA2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA3 +
RPA3 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA4 +
RPA4 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPTOR +
RPTOR is altered in 1.51% of ovarian carcinoma patients [2].
RPTOR is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
SLX4 +
SLX4 is altered in 2.24% of ovarian carcinoma patients [2].
SLX4 is an inclusion eligibility criterion in 13 clinical trials for ovarian carcinoma, of which 9 are open and 4 are closed. Of the trials that contain SLX4 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 1 is phase 3 (0 open) [3].
SMARCA4 +
SMARCA4 is altered in 3.89% of ovarian carcinoma patients [2].
SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SMARCB1 +
SMARCB1 is altered in 1.1% of ovarian carcinoma patients [2].
SMARCB1 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain SMARCB1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
SRC +
SRC is altered in 0.66% of ovarian carcinoma patients [2].
SRC is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SRC status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
SSBP1 +
SSBP1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
STAG2 +
STAG2 is altered in 1.99% of ovarian carcinoma patients [2].
STAG2 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 3 are open and 2 are closed. Of the trials that contain STAG2 status and ovarian carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
STK11 +
STK11 is altered in 1.35% of ovarian carcinoma patients [2].
STK11 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain STK11 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 1/phase 2 (1 open) [3].
TP53 +
TP53 is altered in 74.28% of ovarian carcinoma patients [2].
TP53 is an inclusion eligibility criterion in 7 clinical trials for ovarian carcinoma, of which 2 are open and 5 are closed. Of the trials that contain TP53 status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [3].
TSC1 +
TSC1 is altered in 1.27% of ovarian carcinoma patients [2].
TSC1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
TSC2 +
TSC2 is altered in 4.09% of ovarian carcinoma patients [2].
TSC2 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
XRCC1 +
XRCC1 is altered in 3.25% of ovarian carcinoma patients [2].
XRCC1 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain XRCC1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
